Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105-2122.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.2.2022. nccn.org. Accessed May 4, 2022.
Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38:1346-1366.
Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26:5569-75.
Fasching PA, Gass P, Häberle L, et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Res Treat. 2019;175:617-625.
Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki-67 in breast cancer: Updated recommendations from the International Ki-67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113:808-819.
Dowsett M, Nielsen TO, Ahern R, et al. Assessment of Ki-67 in breast cancer: Recommendations from the International Ki-67 in Breast Cancer Working Group. J Natl Cancer Inst 2011;103:1656-1664.
Johnston SRD, Harbeck N, Hegg, R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3997.
Nielson G, Gu Y, Weaver A, et al. Development of a novel clinical trial immunohistochemistry (IHC) assay using Ki-67, clone MIB-1, monoclonal antibody for Dako Omnis. Presented at the 2020 Congress of the ESP and XXXIII International Congress of the IAP. Abstract PS-01-045.
US Food and Drug Administration. Ki-67 IHC MIB-1 pharmDx (Dako Omnis) - P210026. fda.gov/medical-devices/recently-approved-devices/ki-67-ihc-mib-1-pharmdx-dako-omnis-p210026. Accessed May 4, 2022.
Gluz O, Nitz UA, Christgen M, et al. West German Study Group phase III planB trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34:2341-2348.
Shah M, Nunes MR, Stearns V, et al. CDK4/6 inhibitors: Game changers in the management of hormone receptor–positive advanced breast cancer? Oncology (Williston Park). 2018;32:216-222.
Mayer EM, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): Interim analysis of a multicenter, open-label, randomized, phase 3 study. Lancet Oncol. 2021;22:212-222.
Loibl SL, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—The PENELOPE-B trial. J Clin Oncol. 2021;39:1518-1530.
Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32:1571-1581.
Slamon DJ, Fasching PA, Patel, R, et al. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC). Presented at: ASCO Annual Meeting 2019; May 31 - June 4, 2019. Abstract TPS597.
O’Shaughnessy J, Rastogi P, Harbeck N, et al. Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE. ESMO Virtual Plenary Abstracts. 2021;32:1646-1649. Abstract VP8-2021.
O’Shaughnessy JA, Johnston S, Harbeck N, et al. Primary outcome analysis of invasive disease-free survival for monarchE: Abemaciclib combined with adjuvant endocrine therapy for high-risk early breast cancer. Presented at: 2020 San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS1-01.
Harbeck N, Rastogi P, Shahir A, et al. Letter to the Editor for adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2022;33:227-228.
Rugo HS, O'Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;Epub ahead of print.
Toi, M, Harbeck N, Puig JM, et al. Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT), and interstitial lung disease (ILD) in monarchE. Presented at: ESMO Breast Cancer Virtual Congress; May 5-8, 2021. Abstract 440.
Giordano SH, Freedman RA, Somerfield MR; et al. Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update. J Clin Oncol. 2022;40:307-309.
Abemaciclib [prescribing information]. Indianapolis, IN: Lilly USA LLC; 2021.